Skip to main content
SpringerLink
Log in

Anti-arrhythmic Drugs

  • Chapter
  • First Online:
Clinical Handbook of Cardiac Electrophysiology

  • 1859 Accesses

Abstract

Anti-arrhythmic drugs (AAD’s) alter the electrical properties of the heart principally by either prolonging the cardiac action potential, decreasing conduction velocity, reducing focal automaticity or a combination of these effects. Despite the fact that a large number of AAD’s were initially developed for ventricular arrhythmias the most common current indication is actually AF.

Although the majority of these drugs act relatively specifically on certain receptors the overall general distribution of these receptors throughout the ventricular and atrial myocardium may result in unwanted effects such as Torsades de Pointes (TdP) predominantly with class IA and class III drugs, prolongation of AV conduction, QRS widening and monomorphic VT with class IC drugs.

A meta-analysis of 44 trials involving 11,322 patients showed that all AAD’s were associated with an increased risk of proarrhythmia with the exception of amiodarone and propafenone (Lafuente-Lafuente et al. Arch Intern Med 166:719–28, 2006). Although amiodarone is a very useful agent in the treatment of both atrial and ventricular arrhythmias its use is often limited as a result of its potential long term non-cardiac side effects which limit its use (Rothenberg et al. Heart Dis Stroke 3:19–23, 1994).

More recently, “atrial selective” AAD’s have been developed which may have improved efficacy with better side effect profile. Additionally some drugs (such as renin-angiotensin aldosterone inhibitors and anti-inflammatory agents) may affect the underlying substrate and be indirectly antiarrhythmic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719–28.

    Article  CAS  PubMed  Google Scholar 

  2. Rothenberg F, Franklin JO, DeMaio SJ. Use, value, and toxicity of amiodarone. Heart Dis Stroke. 1994;3:19–23.

    CAS  PubMed  Google Scholar 

  3. Jusko W, Evans W, Schentag J. Applied pharmacokinetics: principles of therapeutic drug monitoring. San Francisco: Applied Therapeutics; 1980. p. 618–38.

    Google Scholar 

  4. Atkinson A, Ruo T. Pharmacokinetics of N-acetylprocainamide. Angiology. 1986;37:959–67.

    PubMed  Google Scholar 

  5. Fuster V, Ryden LE, Cannom DS, et al. European Heart Rhythm Association, Heart Rhythm Society, ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol. 2006;48:854–906.

    Google Scholar 

  6. Podrid PJ, Lampert S, Graboys TB, et al. Aggravation of arrhythmia by antiarrhythmic drugs – incidence and predictors. Am J Cardiol. 1987;59:38E–44.

    Article  CAS  PubMed  Google Scholar 

  7. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol. 2008;127:299–306.

    Article  PubMed  Google Scholar 

  9. Brogan BL, Olsen NJ. Drug-induced rheumatic syndromes. Curr Opin Rheumatol. 2003;15:76.

    Article  PubMed  Google Scholar 

  10. Katkov W, Ellrodt AG. Neutropenia and procainamide. Am Heart J. 1985;110:1321–2.

    Article  CAS  PubMed  Google Scholar 

  11. Gorgels AP, Van der Dool A, Hofs A, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol. 1996;78:43–6.

    Article  CAS  PubMed  Google Scholar 

  12. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990;82:1106–16.

    Article  CAS  PubMed  Google Scholar 

  13. Reimold SC, Chalmers TC, Berlin JA, Antman EM. Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: observations on the role of trial design and implications of drug-related mortality. Am Heart J. 1992;124:924–32.

    Article  CAS  PubMed  Google Scholar 

  14. Grace AA, Camm AJ. Quinidine. N Engl J Med. 1998;338:35–45.

    Article  CAS  PubMed  Google Scholar 

  15. Thibault B, Nattel S. Optimal management with Class I and Class III antiarrhythmic drugs should be done in the outpatient setting: protagonist. J Cardiovasc Electrophysiol. 1999;10:472–81.

    Article  CAS  PubMed  Google Scholar 

  16. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110:1731–7.

    Article  PubMed  Google Scholar 

  17. Tsai CF, Chen SA, Tai CT, et al. Idiopathic ventricular fibrillation: clinical, electrophysiologic characteristics and long-term outcomes. Int J Cardiol. 1998;64:47–55.

    Article  CAS  PubMed  Google Scholar 

  18. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol. 2001;12:268–72.

    Article  CAS  PubMed  Google Scholar 

  19. Karlson BW, Torstensson I, Abjorn C, et al. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J. 1988;3:284–90.

    Google Scholar 

  20. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med. 1982;307:997–9.

    Article  CAS  PubMed  Google Scholar 

  21. Lie KI, Wellens HJ, van Capelle FJ, Durrer D. Lidocaine in the prevention of primary ventricular fibrillation: a double-blind, randomized study of 212 consecutive patients. N Engl J Med. 1974;291:1324–6.

    Article  CAS  PubMed  Google Scholar 

  22. MacMahon S, Collins R, Peto R, et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA. 1988;260:1910–6.

    Article  CAS  PubMed  Google Scholar 

  23. Herlitz J, Bang A, Holmberg M, et al. Rhythm changes during resuscitation from ventricular fibrillation in relation to delay until defibrillation, number of shocks delivered and survival. Resuscitation. 1997;34:17–22.

    Article  CAS  PubMed  Google Scholar 

  24. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346:884–90.

    Article  CAS  PubMed  Google Scholar 

  25. Weaver WD, Fahrenbruch CE, Johnson DD, et al. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation. 1990;82:2027–34.

    Article  CAS  PubMed  Google Scholar 

  26. Roos JC, Paalman ACA, Dunning AJ. Electrophysiologic effects of mexiletine in man. Br Heart J. 1976;38:62.

    Article  Google Scholar 

  27. McCornish M, Robinson C, Kitson D, et al. Clinical electrophysiologic effects of mexiletine. Postgrad Med. 1977;33(Suppl):85.

    Google Scholar 

  28. Campbell RW. Mexiletine. N Engl J Med. 1987;316:29–34.

    Article  CAS  PubMed  Google Scholar 

  29. Chimienti M, Cullen MT, Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. Am J Cardiol. 1996;77:60A–75.

    Article  CAS  PubMed  Google Scholar 

  30. Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol. 1996;77:66A–71.

    Article  CAS  PubMed  Google Scholar 

  31. Martinez-Marcos FJ, Garcia-Garmendia JL, et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol. 2000;86:950–3.

    Article  CAS  PubMed  Google Scholar 

  32. Alp NJ, Bell JA, Shahi M. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart. 2000;84:37–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med. 2004;351:2384–91.

    Article  CAS  PubMed  Google Scholar 

  34. Alboni P, Botto GL, Boriani G, et al. Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during ‘pill-in-the-pocket’ treatment. Heart. 2010;96:546–9.

    Article  CAS  PubMed  Google Scholar 

  35. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989;321:406–12.

    Google Scholar 

  36. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–54.

    Article  CAS  PubMed  Google Scholar 

  37. Tsolakas TC, Davies JP, Oram S. Propranolol in attempted maintenance of sinus rhythm after electrical defibrillation. Lancet. 1964;18:1064.

    Article  Google Scholar 

  38. Plewan A, Lehmann G, Ndrepepa G, et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J. 2001;22:1504–10.

    Article  CAS  PubMed  Google Scholar 

  39. Kuhlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2000;36:139–46.

    Article  CAS  PubMed  Google Scholar 

  40. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol. 2007;49:329–37.

    Article  PubMed  Google Scholar 

  41. Hallstrom AP, Cobb LA, Yu BH, et al. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol. 1991;68:1025–31.

    Article  CAS  PubMed  Google Scholar 

  42. Freemantle N, Cleland J, Young P, et al. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784–94.

    Article  PubMed  Google Scholar 

  44. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol. Lancet. 1996;348:7–12.

    Article  CAS  PubMed  Google Scholar 

  45. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913–20.

    Article  CAS  PubMed  Google Scholar 

  46. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med. 1993;329:452–8.

    Article  CAS  PubMed  Google Scholar 

  47. Roden DM. Usefulness of sotalol for life-threatening ventricular arrhythmias. Am J Cardiol. 1993;72:51A–5.

    Article  CAS  PubMed  Google Scholar 

  48. Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d, l-sotalol. Circulation. 1996;94:2535–4251.

    Article  CAS  PubMed  Google Scholar 

  49. Singh BN, Wellens HJ, Hockings BE. Electropharmacological control of cardiac arrhythmias. New York: Futura Publishing Co; 1994.

    Google Scholar 

  50. Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Heart Rhythm. 2007;4:1250–9.

    Article  PubMed  Google Scholar 

  51. Vassallo P, Trohman RG. Prescribing amiodarone. An evidence-based review of clinical indications. JAMA. 2007;298:1312–22.

    Article  CAS  PubMed  Google Scholar 

  52. Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481–7.

    Article  CAS  PubMed  Google Scholar 

  53. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987–99.

    Article  CAS  PubMed  Google Scholar 

  54. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156:527–9.

    Article  PubMed  Google Scholar 

  55. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–87.

    Article  PubMed  Google Scholar 

  56. Hohnloser SH, Crijns H, Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–78.

    Article  CAS  PubMed  Google Scholar 

  57. Van Noord T, Van Gelder IC, Tieleman RG, et al. VERDICT: the Verapamil versus Digoxin Cardioversion Trial: a randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2001;12:766–9.

    Article  PubMed  Google Scholar 

  58. Patten M, Maas R, Bauer P, et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. Eur Heart J. 2004;25:1395–404.

    Article  PubMed  Google Scholar 

  59. Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25:1385–94.

    Article  PubMed  Google Scholar 

  60. Sticherling C, Oral H, Horrocks J, et al. Effects of Digoxin on acute, atrial fibrillation – induced changes in atrial refractoriness. Circulation. 2000;102:2503–8.

    Article  CAS  PubMed  Google Scholar 

  61. Lerman BB, Belardinelli L. Cardiac electrophysiology of adenosine. Basic and clinical concepts. Circulation. 1991;83:1499–509.

    Article  CAS  PubMed  Google Scholar 

  62. Platia E, McGovern B, Scheinman MM, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Ann Intern Med. 1990;113:104–10.

    Article  PubMed  Google Scholar 

  63. DiMarco JP, Sellers TD, Lerman BB, et al. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J Am Coll Cardiol. 1985;6:417–25.

    Article  CAS  PubMed  Google Scholar 

  64. Di Francesco D, Camm JA. Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757–65.

    Article  Google Scholar 

  65. Calo L, Rebecchi M, Sette A, et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm. 2010;7:1318–23.

    Article  PubMed  Google Scholar 

  66. Roy D, Pratt CM, Torp-Pedersen C, et al. Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518–25.

    Google Scholar 

  67. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116:1647–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiac Electrophysiology, Queens University, Kingston, ON, Canada

    Benedict M. Glover

  2. Division of Cardiology, University of Toronto, Toronto, ON, Canada

    Paul Dorian

  3. Cardiac Electrophysiologist at St. Michael’s Hospital, Toronto, ON, Canada

    Paul Dorian

Authors
  1. Benedict M. Glover
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Dorian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benedict M. Glover .

Editor information

Editors and Affiliations

  1. Queens University , Kingston, Ontario, Canada

    Benedict M. Glover

  2. Cardiovascular Division, Free University of Brussels, Brussels, Belgium

    Pedro Brugada

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Glover, B.M., Dorian, P. (2016). Anti-arrhythmic Drugs. In: Glover, B., Brugada, P. (eds) Clinical Handbook of Cardiac Electrophysiology. Springer, Cham. https://doi.org/10.1007/978-3-319-40818-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-40818-7_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-40816-3

  • Online ISBN: 978-3-319-40818-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation